Bellevue Group AG Sells 109,107 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bellevue Group AG decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 70.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,151 shares of the medical research company's stock after selling 109,107 shares during the quarter. Bellevue Group AG owned approximately 0.16% of Bio-Rad Laboratories worth $15,441,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BIO. First Eagle Investment Management LLC raised its stake in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock valued at $173,773,000 after purchasing an additional 634,311 shares during the period. Swedbank AB bought a new position in shares of Bio-Rad Laboratories during the first quarter worth about $1,824,000. Principal Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock valued at $14,836,000 after purchasing an additional 21,669 shares during the period. Mawer Investment Management Ltd. boosted its position in Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after acquiring an additional 84,237 shares during the period. Finally, Harbor Capital Advisors Inc. raised its position in shares of Bio-Rad Laboratories by 320.6% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 3,663 shares of the medical research company's stock worth $1,000,000 after buying an additional 2,792 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at $48,582.03. This represents a 80.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of the firm's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. This represents a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BIO has been the topic of a number of research reports. Royal Bank of Canada boosted their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Citigroup boosted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective for the company. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of NYSE BIO traded up $2.05 during midday trading on Friday, reaching $340.53. The company's stock had a trading volume of 78,237 shares, compared to its average volume of 197,129. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a 50 day simple moving average of $340.77 and a 200-day simple moving average of $317.92. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of -12.46 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period in the prior year, the company posted $2.33 earnings per share. Bio-Rad Laboratories's revenue was up 2.8% compared to the same quarter last year. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.